WEKO3
アイテム
Experimental alpha-radioimmunotherapy for tumors that have acquired resistance to antibody therapy
https://repo.qst.go.jp/records/2002108
https://repo.qst.go.jp/records/20021082e6c278d-b314-432b-a806-c18294d9a902
| アイテムタイプ | 会議発表用資料 / Presentation(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-06-23 | |||||||||
| タイトル | ||||||||||
| タイトル | Experimental alpha-radioimmunotherapy for tumors that have acquired resistance to antibody therapy | |||||||||
| 言語 | en | |||||||||
| 言語 | ||||||||||
| 言語 | eng | |||||||||
| 資源タイプ | ||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6670 | |||||||||
| 資源タイプ | conference poster | |||||||||
| 著者 |
Hasegawa Sumitaka
× Hasegawa Sumitaka
× Huizi Li
|
|||||||||
| 抄録 | ||||||||||
| 内容記述 | IntroductionRecent progress on radioisotope production accelerates targeted radionuclide therapy or radioimmunotherapy (RIT) for the management of cancer. A radionuclide astatine-211 emits alpha-particles in the process of its decay and has potential for cancer treatment. Uterine serous carcinoma (USC) is a rare but aggressive uterine cancer and overexpression of HER2 protein is seen in about one-third of the patients. Trastuzumab, an antibody drug reacting to HER2 protein, has been proposed as a drug against HER2-positive USC; however, the therapeutic effect is limited because of acquired resistance to trastuzumab. The aim of this study is to investigate the therapeutic potential of alpha-RIT using astatine-211-armed trastuzumab (At-211-Tras) against trastuzumab-resistant USC that metastasized into peritoneal cavity (USC-PM) in a mouse model.Materials and Methods:Animal experiments were carried out with permission and under the regulations of the Institutional Animal Care and Use Committee of Experimental Animals of National Institutes for Quantum Science and Technology, Japan. A mouse model of USC-PM was generated by a transplantation of luciferase genes-introduced human USC cells into peritoneal cavity of immunodeficiency mice. Tumor growth was monitored by in vivo chemiluminescence imaging. After generating the USC-PM mouse model and confirming tumor growth in the peritoneal cavity, antibody therapy (400 μg of trastuzumab per mouse by intraperitoneal injection, twice a week for 5 weeks) was performed. After confirming subsequent re-growth of USC cells in peritoneal cavities, a single dose of At-211-Tras (1 MBq) was administered into the peritoneal cavities. The authors declare no conflicts of interest associated with this presentation.Result and discussion:Tumor changes were approximately 600, 500, 400, and 200 % from the initial tumor sizes at 2 weeks after treatment of PBS only, Tras, 1 MBq of At-211-HuIgG, or 1 MBq of At-211-Tras, respectively. These data suggest that a single dose of At-211-Tras suppressed the tumor growth of HER2 positive USC-PM in mice compared to other control groups. At-211-Tras showed a transient reduction of white blood cell count at 1 week after the administration, but a comparable level of white blood cell count compared to other groups at 4 weeks after the administration. Conclusion:Alpha-RIT using alpha-emitting trastuzumab may be an effective treatment option for USC resistant to trastuzumab therapy. | |||||||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||||||
| 内容記述 | EACR 2025 Congress: Innovative Cancer Science | |||||||||
| 発表年月日 | ||||||||||
| 日付 | 2025-06-18 | |||||||||
